CN112940967B - 一株发酵乳杆菌mf423及其发酵米糠提取物和它们的应用 - Google Patents
一株发酵乳杆菌mf423及其发酵米糠提取物和它们的应用 Download PDFInfo
- Publication number
- CN112940967B CN112940967B CN202110165341.4A CN202110165341A CN112940967B CN 112940967 B CN112940967 B CN 112940967B CN 202110165341 A CN202110165341 A CN 202110165341A CN 112940967 B CN112940967 B CN 112940967B
- Authority
- CN
- China
- Prior art keywords
- rice bran
- lactobacillus fermentum
- bran extract
- fermented rice
- fermented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000209094 Oryza Species 0.000 title claims abstract description 103
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 103
- 235000009566 rice Nutrition 0.000 title claims abstract description 103
- 239000000284 extract Substances 0.000 title claims abstract description 84
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 56
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 56
- 238000000855 fermentation Methods 0.000 claims abstract description 37
- 230000004151 fermentation Effects 0.000 claims abstract description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 20
- 239000008103 glucose Substances 0.000 claims abstract description 20
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 14
- 230000006372 lipid accumulation Effects 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 238000001727 in vivo Methods 0.000 claims abstract description 5
- 210000004185 liver Anatomy 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 9
- 238000006460 hydrolysis reaction Methods 0.000 claims description 9
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 102000016938 Catalase Human genes 0.000 claims description 3
- 108010053835 Catalase Proteins 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 16
- 230000003078 antioxidant effect Effects 0.000 abstract description 12
- 241000186660 Lactobacillus Species 0.000 abstract description 11
- 229940039696 lactobacillus Drugs 0.000 abstract description 11
- 239000001963 growth medium Substances 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 235000013312 flour Nutrition 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 239000002351 wastewater Substances 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 48
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000002000 scavenging effect Effects 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000021329 brown rice Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000021107 fermented food Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 235000021190 leftovers Nutrition 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/115—Cereal fibre products, e.g. bran, husk
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及微生物技术领域,具体涉及一株来源米粉发酵废水的乳酸杆菌(Lactobacillus fermentum)MF423及应用。本发明的乳酸杆菌(Lactobacillus fermentum)MF423发酵米糠提取物在体内和体外均具有改善胰岛素抵抗的功效。经测定,在细胞和动物水平上,该菌发酵米糠提取物均有较高的抗氧化活性,能够显著增加细胞对培养基中葡萄糖的消耗量、降低小鼠血糖,明显清除小鼠脂质积聚,抑制低度炎症的发生,对后续高效利用低值资源米糠和其在临床2型糖尿病治疗应用中具有重要价值。
Description
技术领域
本发明涉及微生物技术领域,具体涉及一株发酵乳杆菌MF423及其发酵米糠提取物和它们的应用。
背景技术
乳酸菌(Lactic acid bacteria,LAB)是一类产乳酸的革兰氏阳性、过氧化氢酶阴性菌,分布极为广泛,并且具有丰富的物种多样性,共200多种,且大多数具有多种生理功能。乳酸菌在自然界中分布很广,植物体表、乳制品、肉制品、啤酒、葡萄酒、果汁、麦芽汁、发酵面团、污水以及人畜粪便中,均可分离到。除了乳酸菌自身具有多种益生作用外,其在食品发酵过程中,还可生成多种功能活性成分。乳酸菌发酵除了可以获得多种对健康有益的活性物质外,它在改善食品风味和提高食品价值上也具有重要的作用。
我国是农业大国,各类农副产品下脚料产量较高,如米糠、麸皮等,开发程度低,往往不能得到很好的利用,造成巨大的浪费。水稻是一种重要的谷类作物,是世界上一半以上人口的主食。米糠是碾米过程中,从糙米(去壳)的外层获得的。糙米的总重量中,米糠约占10%,富含蛋白质、矿物质、脂肪酸、纤维和脂肪酸等多种营养元素。由于米糠具有良好的特性,所以可用于高附加值食品或功能性食品的开发。然而,目前米糠的综合利用率极低,超过90%米糠的被直接作为牛和家禽的饲料原料,缺乏有关米糠高值化利用的系统研究。
在食品开发过程中,微生物发酵技术为我们提供了很好的解决方案。微生物发酵食品,在世界范围内都很普遍。发酵技术在传统食品行业中的使用十分广泛,比如常见的制醋技术、酿酒技术等。我国传统的发酵食品也很多,如馒头、米酒、酱油以及米粉、腐乳等。益生菌发酵食品是功能性食品市场的重要组成部分,占功能性食品市场的60%-70%。乳酸菌被列入卫生部办公厅组织制定的《可用于食品的菌种名单》,因此乳酸菌来源的食品通常被认为是安全的,这保证了发酵产物的安全性。国内外已有一些研究发酵米糠能提高其营养价值,但目前没有研究发现利用乳酸菌发酵米糠以提高其营养价值,且总体来看,米糠的利用率仍然较低。要实现米糠高值化利用,乳酸菌发酵无疑是一种有效手段。
发明内容
本发明的首要目的在于提供一株发酵乳杆菌(Lactobacillus fermentum)MF423及其应用。
一株发酵乳杆菌,分类命名为(Lactobacillus fermentum)MF423,所述(Lactobacillus fermentum)MF423菌株已于2020年10月8日保藏于中国典型培养物保藏中心(CCTCC),地址:中国湖北省武汉市武汉大学,保藏编号为CCTCC No.M 2020573。
所述发酵乳杆菌(Lactobacillus fermentum)MF423分离自米粉发酵废水。
该菌在MRS平板上培养24h后的菌落呈白色,圆形,表面光滑,边缘整齐;革兰氏染色为阳性,菌体杆状。发酵乳杆菌MF423经生理生化测定,接触酶试验为阳性,甲基红试验为阴性,V-P试验为阴性,淀粉水解、琼脂水解、吐温80水解为阴性,生长温度为4-30℃。
该菌的16S rDNA核苷酸序列如SEQ ID NO:1所示。
本发明的第二个目的是提供一种发酵米糠提取物,是由所述的发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠获得。
所述的发酵米糠提取物,将发酵乳杆菌(Lactobacillus fermentum)MF423按1-2%接种量接种发酵培养基,以4~6%米糠为底物,37℃培养箱中静置培养16~36h,离心除菌体和米糠残渣即得。
本发明的第三个目的是提供所述的发酵乳杆菌的应用,具体是用于米糠发酵,获得发酵米糠提取物。
本发明的第四个目的是提供所述的发酵米糠提取物的应用,至少包括以下任一种:
(1)清除羟自由基;
(2)清除细胞胞内的ROS;
(3)清除细胞中脂质积聚;
(4)增加细胞的葡萄糖消耗量;
(5)保护肝脏、增强肝脏抗氧化能力;
(6)降低血糖;
(7)清除体内脂质积聚;
(8)降低炎症因子的水平。
进一步地,
所述(1)中清除体外或者细胞内羟自由基;
所述(2)中清除对HepG2细胞中脂质积累;
所述(3)中增加HepG2细胞的葡萄糖消耗量;
所述的发酵米糠提取物还至少包括以下任一种的应用:
1)增强肝中GSH-PX、T-AOC和SOD水平,同时降低MDA含量;
2)降低血清和肝脏中TC,LDL含量,并同时增加HDL含量;
3)降低的TNF-α、IL-1β和MCP-1水平。
本发明的第五个目的是提供所述的发酵米糠提取物在制备至少包括达到以下任一种功能制剂中的应用,
(1)清除羟自由基;
(2)清除细胞胞内的ROS;
(3)清除细胞中脂质积聚;
(4)增加细胞的葡萄糖消耗量;
(5)保护肝脏、增强肝脏抗氧化能力;
(6)降低血糖;
(7)清除体内脂质积聚;
(8)降低炎症因子的水平。
进一步地,
所述(1)中清除体外或者细胞内羟自由基;
所述(2)中清除对HepG2细胞中脂质积累;
所述(3)中增加HepG2细胞的葡萄糖消耗量;
本发明还包括以下应用,提供所述的发酵米糠提取物在制备至少包括达到以下任一种功能制剂中的应用,
1)增强肝中GSH-PX、T-AOC和SOD水平,同时降低MDA含量;
2)降低血清和肝脏中TC,LDL含量,并同时增加HDL含量;
3)降低的TNF-α、IL-1β和MCP-1水平。
本发明乳酸菌发酵米糠提取物能够清除羟自由基、清除细胞胞内的ROS、清除细胞中脂质积聚、增加细胞的葡萄糖消耗量、保护肝脏、增强肝脏抗氧化能力、降低血糖、清除体内脂质积聚、降低炎症因子的水平等。因此,本发明的乳酸菌发酵米糠提取物在体内和体外均具有改善胰岛素抵抗的功效。经测定,在细胞和动物水平上,该乳酸菌发酵米糠提取物均有较高的抗氧化活性,能够显著降低葡萄糖含量和明显清除脂质积聚以及抑制低度炎症的发生,还有保肝护肝的作用。对后续高效利用低值资源米糠和其在临床2型糖尿病治疗应用中具有重要价值。
附图说明
图1.发酵乳杆菌(Lactobacillus fermentum)MF423的扫描电镜照片(50000倍);
图2.发酵乳杆菌(Lactobacillus fermentum)MF423及部分相关菌株依据16SrDNA序列构建的系统发育树;
图3.三株不同的乳杆菌发酵米糠提取物的体外抗氧化活性。
图4.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对细胞胞内ROS的清除功效;
图5.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对过氧化氢刺激HaCaT细胞的预保护作用;
图6.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对HepG2细胞中脂质积累的清除作用;
图7.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物增加HepG2细胞中葡萄糖消耗量的作用;
图8.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对C57小鼠肝脏的保护作用;
图9.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对C57小鼠的抗氧化活性;
图10.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物降低C57小鼠血糖水平;
图11.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物降低C57小鼠脂质水平;
图12.发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物降低C57小鼠炎症因子水平。
具体实施方式
以下结合说明书附图和具体实施例进一步解释本发明,但不对本发明构成任何限定。以下实施例中除特殊说明外,均为本领域常规试剂和方法步骤。
实施例1发酵乳杆菌(Lactobacillus fermentum)MF423的分离样品处理:吸取保存于4℃的米粉发酵废水500μL,分别吸取50μL、100μL、200μL在MRS固体培养基平板上涂布,每个涂布量设置三个重复,然后置于37℃恒温箱中静置培养。待各个菌落长好后,反复平板划线,分离纯化,最终得到菌株MF423。
实施例2菌株MF423生物学性状及生理生化和分子鉴定
S1.形态特征:菌株MF423在扫描电镜下的形态见图1,该菌株在MRS固体培养基平板培养24h菌落形态为:菌落呈白色,圆形,表面光滑,边缘整齐;革兰氏染色为阳性,菌体杆状。
S2.生理生化特征:本发明的菌株MF423经生理生化测定,接触酶试验为阳性,甲基红试验为阴性,V-P试验为阴性,淀粉水解、琼脂水解、吐温80水解为阴性,生长温度为4-30℃。
见表1。
表1发酵乳杆菌MF423生理生化特征
注:+,阳性;-,阴性;WH,白色;R,杆状
S3.菌株MF423的16S rDNA的序列测定与分析
S31.PCR模板DNA的快速制备:将菌株MF423划线接种在MRS培养基的平板上,37℃培养过夜。取单一菌落悬浮于10mL ddH2O中,沸水浴加热5min,离心,取上清作为PCR模板DNA。
S32.16S rDNA基因PCR扩增
PCR引物由华大基因合成。
Primer A:5′-AGAGTTTGATCCTGGCTCAG-3′
Primer B:5′-ACGGCTACCTTGTTACGACTT-3′
PCR反应体系如下:
10×PCR buffer 2mmol/L d NTP | 5μL |
Primer A | 5μL |
Primer B | 1μM |
5U/μL Taq DNAPolymerase | 1μM |
25mM MgCl<sub>2</sub> | 1.25U |
Template DNA | 4mM |
Water,nuclease-free to | 0.5μg |
10×PCR buffer 2mmol/L d NTP | 50μL |
PCR扩增条件:95℃ 5min,94℃ 30s,55℃ 30s,72℃ 90s,30个循环;72℃ 10min。
序列测定:PCR产物纯化后,送擎科生物测序,其序列如SEQ ID NO:1所示。该序列与GenBank数据库中的已知序列进行BLAST比较分析,并从数据库获得相关种属的16S rDNA序列,构建系统发育树,见图2。经比较分析发现,本发明的发酵乳杆菌MF423与菌株(Lactobacillus fermentum)6012(MT463735.1)近,菌株MF423的16S rDNA序列与(Lactobacillus fermentum)6012(MT463735.1)有99%的同源性。
综合16S rDNA序列分析、生理生化特性分析,表明本发明属于发酵乳杆菌,命名为发酵乳杆菌(Lactobacillus fermentum)MF423,所述(Lactobacillus fermentum)MF423菌株已于2020年10月8日保藏于中国典型培养物保藏中心(CCTCC),保藏编号为CCTCCM2020573。
实施例3三株不同的乳杆菌发酵米糠提取物的体外抗氧化活性
将三株乳杆菌分别接种于MRS液体培养基,37℃静置培养24h,按2%分别接种发酵培养基,37℃静置培养,取发酵24h的发酵液,10000rpm离心两次除菌体和米糠残渣,取上层发酵液测定羟自由基清除活性:向干净的EP管中加入40μL Fe2+,随后加入40μL OP,混匀,溶液变成橘红色配合物,向实验组(As)和阴性对照组(An)中加入80μL样品,空白对照组(Ab)加入80μL dd H2O,混合均匀以后,启动反应,实验组(As)加入40μL H2O2,阴性对照组(An)加入40μL H2O,空白对照组(Ab)加入40μL H2O2。然后放入50℃水浴锅中孵育30min,取150μL到酶标板中,使用多功能酶标仪测定536nm处的吸光度值,结果如图3,分别为干酪乳杆菌(A)、发酵乳杆菌(Lactobacillus fermentum)MF423(B)、植物乳杆菌(C)发酵米糠不同时间发酵产物的羟自由基清除活性。结果显示发酵乳杆菌在发酵米糠24h时羟自由基清除活性最高。
羟自由基清除活性(HRSA)的计算公式(3-2)如下:
HRSA(%)=[(As-Ab)/(An-Ab)]×100%,
其中As是实验组,An是阴性对照组,Ab是空白对照组,反应后536nm处测定的吸光度值。
发酵培养基(g/100mL):米糠5g,Na2HPO4 0.1g,KH2PO4 0.03g,CaCl2 0.1g,Na2CO30.1g,蒸馏水100mL。
实施例4发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对细胞胞内ROS的清除功效
将发酵乳杆菌(Lactobacillus fermentum)MF423按2%接种量接种发酵培养基,以米糠为底物,37℃培养箱中静置培养24h,离心上清液冻干获得发酵米糠提取物粉末。将状态良好的HUVECs(人脐静脉内皮细胞)和LO2(人正常肝细胞)细胞接种到24孔细胞培养板中,待细胞贴壁完全后,加入含终浓度为35mM葡萄糖的无血清培养基,于37℃培养箱中静置培养12h后,分别加入终浓度为25、50和100μg/mL发酵米糠提取物处理24h。接着加入浓度为10μM的DCFH-DA溶液(用无血清培养基稀释),于37℃静置孵育1h后,用PBS小心清洗三遍,去除多余DCFH-DA。采用倒置荧光显微镜拍摄细胞胞内荧光强度,见图4。图中分别为NC为空白对照组(即正常培养条件下的细胞,不加本发明发酵产物和其他物质),Model为不添加本发明发酵产物,用35mM葡萄糖刺激后建立的氧化应激模型组,后依次为采用35mM葡萄糖刺激细胞产生氧化应激后添加不同浓度发酵产物对细胞ROS的清除效果。结果显示,当加入的发酵产物浓度为25μg/mL时对细胞胞内ROS就有较好的清除作用。
将发酵乳杆菌(Lactobacillus fermentum)MF423按2%接种量接种发酵培养基,以米糠为底物,37℃培养箱中静置培养24h,离心,上清液冻干获得发酵米糠提取物粉末。将状态良好的HaCaT细胞(人永生化角质形成细胞)接种到24孔板中,分别设为空白对照组(Blank control,不添加发酵米糠提取物和其他物质),模型组(Model,即用1.5mM H2O2刺激细胞建立氧化应激模型),米糠未发酵提取物组(Negative control,即不加发酵乳杆菌,但加入米糠和发酵培养基),米糠发酵提取物三个剂量组(25、50和100μg/mL)。待细胞贴壁完全后,分别加入含终浓度为25、50、100μg/mL发酵米糠提取物处理24h,用PBS小心清洗三遍,去除残余的完全培养基,接着加入含1.5mM H2O2的无血清培养基,于37℃静置孵育4h后,接着加入浓度为10μM的DCFH-DA溶液(用无血清培养基稀释),于37℃静置孵育1h后,用PBS小心清洗三遍,去除多余DCFH-DA。采用倒置荧光显微镜拍摄细胞胞内荧光强度,见图5。结果显示,加入的发酵产物浓度达到50μg/mL时就可对过氧化氢刺激细胞有较好的保护作用。
实施例5发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对HepG2细胞中脂质积累的清除作用
将处于对数生长期的HepG2细胞(人肝癌细胞)接种于24孔板中,37℃培养过夜,分别设为空白对照组(NC,不添加发酵米糠提取物和其他物质),模型组(IR),米糠未发酵提取物组(RB,即不加发酵乳杆菌,但加入米糠和发酵培养基),米糠发酵提取物三个剂量组(25、50和100μg/mL)。待细胞密度培养至80%时,更换培养基为无血清和酚红的DMEM培养基,除NC组外,其余各组添加浓度为0.15mM棕榈酸和0.20mM油酸共同作用细胞,建立细胞胰岛素抵抗模型。处理12h后,用PBS清洗细胞3次,更换为含血清的DMEM培养基。接着分别加入25、50和100μg/mL的发酵提取物和RB(100μg/mL)处理细胞24h后,弃去培养液,PBS洗2-3遍,采用10%甲醛固定30min后用蒸溜水充分清洗干净。然后,采用油红O稀释液染色15min,再用60%异丙醇分化使染色更清晰。最后蒸馏水清洗3遍,于倒置显微镜下观察HepG2细胞的脂肪积累情况并拍照,见图6。结果显示,与NC组相比,IR组细胞脂质显著积累,表明细胞胰岛素抵抗模型成功建立;RB组对脂质清除相较于模型组无明显变化,说明未发酵提取物对细胞脂质无清除作用;米糠发酵提取物则能够显著的清除细胞的脂质积累,并呈现剂量依赖趋势,其中100μg/mL剂量效果最好。
实施例6发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物增加HepG2细胞中葡萄糖消耗量的作用
前期步骤见实施例5,建模成功的HepG2细胞经发酵提取物处理后,收集上清液。采用葡萄糖氧化酶法检测各组细胞消耗葡萄糖含量,见图7。图中NC为正常培养条件下的细胞对照组,IR为细胞胰岛素抵抗模型,RB为未发酵产物,后依次为不同浓度发酵产物对细胞消耗培养基葡萄糖含量效果。结果显示,该菌发酵米糠提取物能够增加HepG2细胞的葡萄糖消耗量。未发酵提取物组对葡萄糖的消耗相较于模型组无明显变化,但是发酵后的提取物能够显著的增加细胞的葡萄糖消耗量,并呈现剂量依赖趋势,其中100μg/mL剂量效果最好。
实施例7发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对C57小鼠肝脏的保护作用
C57BL/6J小鼠60只(♂)体重为18±2g,按体重随机分为2组,即对照组(10只)和模型组(50只)。对照组(NC)小鼠给予正常饲料喂养,模型组小鼠给予高脂饲料喂养,持续8周。将模型组的所有小鼠按剂量为35mg/kg腹腔注射链脲佐菌素,建立小鼠胰岛素抵抗模型。同时随机按体重将模型组小鼠分为5组:模型组(HFD),吡格列酮阳性组(PGLT,30mg/kg),未发酵给药组(RB,1.0g/kg),低剂量发酵提取物组(LFLRB,0.5g/kg)和高剂量发酵提取物组(HLFRB,1.0g/kg)。继续保持高脂饲料喂养,模型组按照等体积的蒸馏水灌胃,每天一次,持续4周。实验结束,小鼠禁食12h后收集肝脏组织,经石蜡包埋和HE染色后,分析发酵提取物对肝脏的保护作用,见图8。结果显示,不同浓度的发酵产物能够明显地减少肝脏的脂滴积聚,减少炎症浸润,较好地保护肝细胞,使其排列整齐和维持正常形态,其中100μg/mL剂量效果最好。
实施例8发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物对C57小鼠的抗氧化活性
前期动物处理步骤见实施例7。实验结束后,收集小鼠的血清,采用生化试剂盒分别检测抗氧化指标丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-PX)、总抗氧化能力(T-AOC)和超氧化物歧化酶(SOD)含量,以分析发酵提取物对小鼠肝脏的抗氧化活性,见图9。
测试结果发现,该菌发酵米糠提取物可以提高小鼠肝脏的抗氧化活性。与高脂模型组相比较,未发酵提取物组的抗氧化指标无明显变化,而发酵提取物组的MDA水平明显下降,GSH-PX、T-AOC和SOD水平则明显升高,并且高剂量组的效果要优于低剂量组。这些结果说明,该菌发酵米糠提取物能够增强小鼠的肝脏抗氧化能力。
实施例9发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物降低C57小鼠血糖水平
前期动物处理步骤见实施例7。实验结束前,通过尾静脉采血检测小鼠的血糖值,以分析该菌发酵提取物对小鼠血糖的影响,见图10。
测试结果发现,该菌发酵米糠提取物能够显著降低小鼠的血糖值。小鼠建立胰岛素抵抗模型,其血糖值稳定维持在13mmol/L水平左右。未发酵提取物的小鼠血糖没有下降的趋势,而发酵提取物的小鼠血糖明显下降,虽然高于对照组水平,但是高、低剂量组仍分别具有48%和34%的降低血糖的能力,从而干预小鼠胰岛素抵抗的发生。
实施例10发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物降低C57小鼠脂质水平
前期动物处理步骤见实施例7。实验结束后,收集小鼠血清和肝脏组织,并制作成肝脏匀浆以便后续分析。采用生化试剂盒分别检测血清和肝脂质的总胆固醇(TC)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)水平,以分析该菌发酵米糠提取物对小鼠脂质的影响,见图11。
测试结果发现,该菌发酵米糠提取物能够显著降低小鼠的脂质水平。胰岛素抵抗模型小鼠的血清和肝脏脂质水平明显升高,经过发酵提取物的处理后,其血清和肝脏的TC和LDL的含量明显降低,HDL含量则明显升高。未发酵提取物处理的小鼠脂质水平未见明显的改变。这一结果说明该菌发酵米糠提取物能显著改善脂质在小鼠体内的积聚,干预小鼠胰岛素抵抗的形成。
实施例11发酵乳杆菌(Lactobacillus fermentum)MF423发酵米糠提取物降低C57小鼠炎症因子水平。
前期动物处理步骤见实施例7。实验结束后,收集小鼠血清,采用Elisa试剂盒检测炎症因子TNF-α、IL-1β和MCP-1水平变化情况,以分析该菌发酵提取物对小鼠炎症发生的影响,见图12。
测试结果发现,该菌发酵米糠提取物能够降低小鼠的炎症因子水平。胰岛素抵抗模型的小鼠常常会伴随着低度炎症的发生,因此模型组小鼠的TNF-α、IL-1β和MCP-1水平明显升高。未发酵提取物处理小鼠后,炎症因子水平无明显变化。但是当给予小鼠发酵提取物处理后,可以观察到小鼠的TNF-α、IL-1β和MCP-1水平明显降低。这一结果说明,该菌发酵米糠提取物能够降低炎症因子水平,改善小鼠胰岛素抵抗的发生。
序列表
<110> 中南大学
<120> 一株发酵乳杆菌MF423及其发酵米糠提取物和它们的应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
agagtttgat cctggctcag 20
<210> 2
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
acggctacct tgttacgact t 21
Claims (8)
1.一株发酵乳杆菌(Lactobacillus fermentum)MF423,保藏编号为CCTCC M 2020573。
2.根据权利要求1所述的发酵乳杆菌,其特征在于,接触酶试验为阳性,甲基红试验为阴性,V-P试验为阴性,淀粉水解、琼脂水解、吐温80水解为阴性。
3.一种发酵米糠提取物,其特征在于,是由权利要求1或2所述的发酵乳杆菌发酵米糠获得。
4.根据权利要求3所述的发酵米糠提取物,其特征在于,将发酵乳杆菌(Lactobacillusfermentum)MF423按1-2%接种量接种发酵培养基,以4~6 %的米糠为底物,37°C培养箱中静置培养16~36 h,离心除菌体和米糠残渣即得。
5.权利要求1或2所述的发酵乳杆菌的应用,其特征在于,用于米糠发酵,获得发酵米糠提取物。
6.权利要求3或4所述的发酵米糠提取物在制备至少包括达到以下任一种功能制剂中的应用,其特征在于,
(1)体外抗氧化;
(2)胰岛素抵抗治疗。
7.根据权利要求6所述的发酵米糠提取物的应用,其特征在于,
所述(2)中包括以下至少一种:
1)清除细胞中脂质积聚;
2)增加细胞的葡萄糖消耗量;
3)保护肝脏、增强肝脏抗氧化能力;
4)降低血糖;
5)清除体内脂质积聚;
6)降低炎症因子的水平。
8.根据权利要求7所述的发酵米糠提取物的应用,其特征在于,所述的炎症因子TNF-α、IL-1β和MCP-1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110165341.4A CN112940967B (zh) | 2021-02-06 | 2021-02-06 | 一株发酵乳杆菌mf423及其发酵米糠提取物和它们的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110165341.4A CN112940967B (zh) | 2021-02-06 | 2021-02-06 | 一株发酵乳杆菌mf423及其发酵米糠提取物和它们的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112940967A CN112940967A (zh) | 2021-06-11 |
CN112940967B true CN112940967B (zh) | 2022-06-21 |
Family
ID=76242973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110165341.4A Active CN112940967B (zh) | 2021-02-06 | 2021-02-06 | 一株发酵乳杆菌mf423及其发酵米糠提取物和它们的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112940967B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114181857B (zh) * | 2021-12-09 | 2023-04-18 | 贵州大学 | 一种抗氧化发酵乳杆菌及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103384529A (zh) * | 2010-12-21 | 2013-11-06 | 雀巢产品技术援助有限公司 | 适合于控制动物血糖的方法和组合物 |
CN103937716A (zh) * | 2014-04-17 | 2014-07-23 | 扬州大学 | 人源发酵乳杆菌grx07及其应用 |
CN110218681A (zh) * | 2019-06-25 | 2019-09-10 | 吉林农业大学 | 一株发酵乳杆菌kp101及其应用 |
-
2021
- 2021-02-06 CN CN202110165341.4A patent/CN112940967B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103384529A (zh) * | 2010-12-21 | 2013-11-06 | 雀巢产品技术援助有限公司 | 适合于控制动物血糖的方法和组合物 |
CN103937716A (zh) * | 2014-04-17 | 2014-07-23 | 扬州大学 | 人源发酵乳杆菌grx07及其应用 |
CN110218681A (zh) * | 2019-06-25 | 2019-09-10 | 吉林农业大学 | 一株发酵乳杆菌kp101及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112940967A (zh) | 2021-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105018379B (zh) | 一株具高抗氧化活性的植物乳杆菌及其应用 | |
CN113604395B (zh) | 一株可发酵石斛且其发酵液可改善皮肤质量的植物乳杆菌 | |
CN110964673B (zh) | 一种具有高抗氧化性及美白效果的戊糖片球菌及其应用 | |
CN113143812B (zh) | 一种卡瓦胡椒发酵物的制备方法和产品及其在化妆品中的应用 | |
CN105132321A (zh) | 一种屎肠球菌及其高密度固态发酵的培养基及方法 | |
CN113842347B (zh) | 具有抗衰老和美白活性的墨红玫瑰灵芝发酵物和墨红玫瑰酶解后发酵物的组合物 | |
CN114032190B (zh) | 一株可发酵石斛且其发酵液可有效修复日光皮炎的罗伊氏乳杆菌 | |
CN112940967B (zh) | 一株发酵乳杆菌mf423及其发酵米糠提取物和它们的应用 | |
KR20210073948A (ko) | 전통발효식품 유래 미생물로 발효되어 면역증가 활성을 가지며, 저작성이 용이한 노인식용 발효 곤드레 부산물의 제조방법 | |
CN102851259A (zh) | 抗氧化剂的制造方法 | |
CN111349678A (zh) | 一种油菜花粉多糖提取方法以及提取产物 | |
CN111449239B (zh) | 一种灵芝菌发酵沙棘籽粕的功能性食品添加物及其制备方法 | |
CN111607621A (zh) | 一种产玫瑰花香的酵母及其在灵武长枣酵素中的应用 | |
CN114437990B (zh) | 戊糖片球菌、菌剂及其应用以及制备低血糖生成指数食品的方法 | |
CN113308419B (zh) | 一株发酵用的谷糠乳杆菌及其应用 | |
CN1986775A (zh) | 适用于淡豆豉纯种发酵的枯草芽孢杆菌菌株 | |
KR100606241B1 (ko) | 항당뇨의 효과가 증강된 홍삼청국장 제조방법 | |
CN113439838B (zh) | 发酵方法、发酵产物及包含其的试剂盒 | |
CN115678797A (zh) | 戊糖片球菌sc009及其应用 | |
CN111363692B (zh) | 一种复合菌剂及其发酵产物的应用 | |
CN109749955B (zh) | 短乳杆菌zj401及其应用 | |
CN113308418A (zh) | 一株发酵用的谷糠乳杆菌及其发酵制备工艺 | |
CN113956993A (zh) | 一株具有缓解细胞氧化损伤作用的干酪乳杆菌 | |
KR101057504B1 (ko) | 바실러스 속 미생물을 함유하는 쌀겨발효용 조성물 | |
CN115873743B (zh) | 一株高产尿囊素的发酵粘液乳杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |